Brokerages Set Agenus Inc. (NASDAQ:AGEN) Price Target at $14.50

Agenus Inc. (NASDAQ:AGEN) has been assigned an average rating of “Moderate Buy” from the four ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $14.50.

A number of brokerages have recently issued reports on AGEN. Wall Street Zen upgraded shares of Agenus from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Zacks Research upgraded shares of Agenus from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 2nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th.

Hedge Funds Weigh In On Agenus

Large investors have recently modified their holdings of the stock. LPL Financial LLC lifted its position in shares of Agenus by 20.3% during the fourth quarter. LPL Financial LLC now owns 23,326 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 3,943 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new position in shares of Agenus during the third quarter worth approximately $64,000. Acadian Asset Management LLC acquired a new position in shares of Agenus during the first quarter worth approximately $58,000. Jump Financial LLC acquired a new position in shares of Agenus during the second quarter worth approximately $55,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Agenus during the fourth quarter worth approximately $54,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Stock Down 4.6%

NASDAQ:AGEN opened at $3.76 on Tuesday. The firm has a market cap of $144.38 million, a PE ratio of -8.17 and a beta of 1.60. Agenus has a 12 month low of $2.63 and a 12 month high of $7.34. The company’s 50-day moving average price is $3.57 and its two-hundred day moving average price is $3.70.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Monday, March 16th. The biotechnology company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of ($1.27) by $1.83. Agenus had a negative net margin of 2.67% and a negative return on equity of 7.65%. The firm had revenue of $34.20 million for the quarter, compared to analyst estimates of $28.10 million. On average, research analysts expect that Agenus will post 1.3 EPS for the current fiscal year.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.